Price T Rowe Associates Inc. MD Increases Holdings in Kymera Therapeutics, Inc. (NASDAQ:KYMR)

Price T Rowe Associates Inc. MD boosted its position in Kymera Therapeutics, Inc. (NASDAQ:KYMR) by 3.4% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 6,870,333 shares of the company’s stock after buying an additional 224,859 shares during the period. Price T Rowe Associates Inc. MD owned approximately 0.11% of Kymera Therapeutics worth $276,395,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds and other institutional investors also recently bought and sold shares of the business. Blue Trust Inc. raised its position in Kymera Therapeutics by 74.8% during the fourth quarter. Blue Trust Inc. now owns 631 shares of the company’s stock valued at $25,000 after acquiring an additional 270 shares in the last quarter. KBC Group NV boosted its position in Kymera Therapeutics by 53.8% during the fourth quarter. KBC Group NV now owns 2,151 shares of the company’s stock worth $87,000 after purchasing an additional 752 shares in the last quarter. Tower Research Capital LLC TRC grew its holdings in Kymera Therapeutics by 95.5% in the fourth quarter. Tower Research Capital LLC TRC now owns 4,812 shares of the company’s stock valued at $194,000 after purchasing an additional 2,350 shares during the period. Summit Investment Advisors Inc. increased its position in shares of Kymera Therapeutics by 9.0% in the fourth quarter. Summit Investment Advisors Inc. now owns 4,912 shares of the company’s stock valued at $198,000 after buying an additional 406 shares in the last quarter. Finally, BI Asset Management Fondsmaeglerselskab A S acquired a new position in shares of Kymera Therapeutics during the 4th quarter worth approximately $251,000.

Kymera Therapeutics Trading Down 0.9 %

Shares of KYMR opened at $33.26 on Friday. The firm has a market capitalization of $2.16 billion, a price-to-earnings ratio of -14.21 and a beta of 2.22. The firm’s fifty day simple moving average is $29.89 and its 200-day simple moving average is $38.61. Kymera Therapeutics, Inc. has a twelve month low of $19.45 and a twelve month high of $53.27.

Kymera Therapeutics (NASDAQ:KYMR) last posted its earnings results on Thursday, February 27th. The company reported ($0.88) EPS for the quarter, missing analysts’ consensus estimates of ($0.76) by ($0.12). The company had revenue of $7.39 million during the quarter, compared to analysts’ expectations of $14.81 million. Kymera Therapeutics had a negative net margin of 191.26% and a negative return on equity of 24.96%. On average, analysts predict that Kymera Therapeutics, Inc. will post -2.79 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of equities research analysts recently issued reports on KYMR shares. Leerink Partners reissued an “outperform” rating and issued a $60.00 price target on shares of Kymera Therapeutics in a research note on Friday, December 27th. Citigroup assumed coverage on Kymera Therapeutics in a report on Thursday, March 13th. They issued a “buy” rating and a $52.00 price objective on the stock. Stephens reaffirmed an “overweight” rating and set a $60.00 target price on shares of Kymera Therapeutics in a research note on Tuesday, January 21st. Finally, HC Wainwright increased their target price on shares of Kymera Therapeutics from $54.00 to $60.00 and gave the company a “buy” rating in a research report on Friday, February 28th. Three research analysts have rated the stock with a hold rating, eleven have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $56.36.

Insider Transactions at Kymera Therapeutics

In other Kymera Therapeutics news, COO Jeremy G. Chadwick sold 1,383 shares of the business’s stock in a transaction on Monday, March 3rd. The shares were sold at an average price of $30.45, for a total transaction of $42,112.35. Following the sale, the chief operating officer now directly owns 67,800 shares in the company, valued at approximately $2,064,510. The trade was a 2.00 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Ellen Chiniara sold 2,241 shares of the company’s stock in a transaction dated Monday, March 3rd. The stock was sold at an average price of $30.45, for a total transaction of $68,238.45. Following the transaction, the insider now owns 80,085 shares in the company, valued at $2,438,588.25. The trade was a 2.72 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 10,659 shares of company stock worth $324,567 over the last 90 days. 15.82% of the stock is currently owned by insiders.

Kymera Therapeutics Profile

Kymera Therapeutics, Inc, a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors.